Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Alan Partin

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Physiology

Disease Progression

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Antonarakis Emmanuel S; Heath Elisabeth I; Walczak Janet R; Nelson William G; Fedor Helen; De Marzo Angelo M; Zahurak Marianna L; Piantadosi Steven; Dannenberg Andrew J; Gurganus Robin T; Baker Sharyn D; Parnes Howard L; DeWeese Theodore L; Partin Alan W; Carducci Michael A
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Jain Alka; McKnight Dianalee A; Fisher Larry W; Humphreys Elizabeth B; Mangold Leslie A; Partin Alan W; Fedarko Neal S
Small integrin-binding proteins as serum markers for prostate cancer detection.
Bañez Lionel L; Sun Leon; Trock Bruce J; Han Misop; Partin Alan W; Aronson William J; Terris Martha K; Presti Joseph C; Kane Christopher J; Amling Christopher L; Moul Judd W; Freedland Stephen J
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Alan Partin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Antonarakis Emmanuel S; Heath Elisabeth I; Walczak Janet R; Nelson William G; Fedor Helen; De Marzo Angelo M; Zahurak Marianna L; Piantadosi Steven; Dannenberg Andrew J; Gurganus Robin T; Baker Sharyn D; Parnes Howard L; DeWeese Theodore L; Partin Alan W; Carducci Michael A
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4986-93.
2009: Jain Alka; McKnight Dianalee A; Fisher Larry W; Humphreys Elizabeth B; Mangold Leslie A; Partin Alan W; Fedarko Neal S
Small integrin-binding proteins as serum markers for prostate cancer detection.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5199-207.
2009: Bañez Lionel L; Sun Leon; Trock Bruce J; Han Misop; Partin Alan W; Aronson William J; Terris Martha K; Presti Joseph C; Kane Christopher J; Amling Christopher L; Moul Judd W; Freedland Stephen J
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
The Journal of urology 2009;182(2):491-6; discussion 496-8.
2009: Kader A Karim; Sun Jielin; Isaacs Sarah D; Wiley Kathleen E; Yan Guifang; Kim Seong-Tae; Fedor Helen; DeMarzo Angelo M; Epstein Jonathan I; Walsh Patrick C; Partin Alan W; Trock Bruce; Zheng S Lilly; Xu Jianfeng; Isaacs William
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
The Prostate 2009;69(11):1195-205.
2009: Leman Eddy S; Magheli Ahmed; Cannon Grant W; Mangold Leslie; Partin Alan W; Getzenberg Robert H
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
The Prostate 2009;69(11):1188-94.
2009: Isharwal Sumit; Miller M Craig; Epstein Jonathan I; Mangold Leslie A; Humphreys Elizabeth; Partin Alan W; Veltri Robert W
DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
Urology 2009;73(5):1092-7.
2009: Rosenzweig C Nicole; Zhang Zhen; Sun Xiaer; Sokoll Lori J; Osborne Katherine; Partin Alan W; Chan Daniel W
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.
The Journal of urology 2009;181(3):1407-14.
2009: Hernandez David J; Han Misop; Humphreys Elizabeth B; Mangold Leslie A; Taneja Samir S; Childs Stacy J; Bartsch Georg; Partin Alan W
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
BJU international 2009;103(5):609-14.
2009: Fujita Kazutoshi; Ewing Charles M; Chan David Y S; Mangold Leslie A; Partin Alan W; Isaacs William B; Pavlovich Christian P
Endoglin (CD105) as a urinary and serum marker of prostate cancer.
International journal of cancer. Journal international du cancer 2009;124(3):664-9.
2009: Hu Rong; Dunn Thomas A; Wei Shuanzeng; Isharwal Sumit; Veltri Robert W; Humphreys Elizabeth; Han Misop; Partin Alan W; Vessella Robert L; Isaacs William B; Bova G Steven; Luo Jun
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Cancer research 2009;69(1):16-22.
2009: Loeb Stacy; Partin Alan W
Randomized trials of prostate cancer screening.
Reviews in urology 2009;11(3):179-80.
2009: Loeb Stacy; Partin Alan W
Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention.
Reviews in urology 2009;11(2):114-5.
2009: Brawer Michael K; Loeb Stacy; Partin Alan W; Yoshimura Naoki; Chancellor Michael B; Roehrborn Claus G; Assimos Dean G; Nickel J Curtis; Shuch B; Pouliot F; Belldegrun Arie S; Shapiro Ellen
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
Reviews in urology 2009;11(2):82-107.
2009: Mozer Pierre C; Partin Alan W; Stoianovici Dan
Robotic image-guided needle interventions of the prostate.
Reviews in urology 2009;11(1):7-15.
2009: Makarov Danil V; Loeb Stacy; Getzenberg Robert H; Partin Alan W
Biomarkers for prostate cancer.
Annual review of medicine 2009;60():139-51.
2008: Isharwal Sumit; Miller Michael Craig; Epstein Jonathan I; Mangold Leslie A; Humphreys Elizabeth; Partin Alan W; Veltri Robert W
Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
International journal of cancer. Journal international du cancer 2008;123(11):2636-43.
2008: Veltri Robert W; Isharwal Sumit; Miller M Craig; Epstein Jonathan I; Mangold Leslie A; Humphreys Elizabeth; Partin Alan W
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
The Prostate 2008;68(16):1806-15.
2008: Alumkal Joshi J; Zhang Zhe; Humphreys Elizabeth B; Bennett Christina; Mangold Leslie A; Carducci Michael A; Partin Alan W; Garrett-Mayer Elizabeth; DeMarzo Angelo M; Herman James G
Effect of DNA methylation on identification of aggressive prostate cancer.
Urology 2008;72(6):1234-9.
2008: Magheli Ahmed; Rais-Bahrami Soroush; Trock Bruce J; Humphreys Elizabeth B; Partin Alan W; Han Misop; Gonzalgo Mark L
Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching.
Urology 2008;72(6):1246-51.
2008: Wu Ina; Nielsen Matthew E; Han Misop; Partin Alan W; Makarov Danil V
Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?
Urology 2008;72(6):1219-23.
2008: Sun Jielin; Zheng Siqun Lilly; Wiklund Fredrik; Isaacs Sarah D; Purcell Lina D; Gao Zhengrong; Hsu Fang-Chi; Kim Seong-Tae; Liu Wennuan; Zhu Yi; Stattin Pär; Adami Hans-Olov; Wiley Kathleen E; Dimitrov Latchezar; Sun Jishan; Li Tao; Turner Aubrey R; Adams Tamara S; Adolfsson Jan; Johansson Jan-Erik; Lowey James; Trock Bruce J; Partin Alan W; Walsh Patrick C; Trent Jeffrey M; Duggan David; Carpten John; Chang Bao-Li; Grönberg Henrik; Isaacs William B; Xu Jianfeng
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.
Nature genetics 2008;40(10):1153-5.
2008: Xu Jianfeng; Isaacs Sarah D; Sun Jielin; Li Ge; Wiley Kathleen E; Zhu Yi; Hsu Fang-Chi; Wiklund Fredrik; Turner Aubrey R; Adams Tamara S; Liu Wennuan; Trock Bruce J; Partin Alan W; Chang Baoli; Walsh Patrick C; Grönberg Henrik; Isaacs William; Zheng Siqun
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5819-24.
2008: Sun Jielin; Chang Bao-Li; Isaacs Sarah D; Wiley Kathleen E; Wiklund Fredrik; Stattin Pär; Duggan David; Carpten John D; Trock Bruce J; Partin Alan W; Walsh Patrick C; Grönberg Henrik; Xu Jianfeng; Isaacs William B; Zheng S Lilly
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
The Prostate 2008;68(12):1257-62.
2008: Sokoll Lori J; Wang Yinghui; Feng Ziding; Kagan Jacob; Partin Alan W; Sanda Martin G; Thompson Ian M; Chan Daniel W
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
The Journal of urology 2008;180(2):539-43; discussion 543.
2008: Zhao Kevin H; Hernandez David J; Han Misop; Humphreys Elizabeth B; Mangold Leslie A; Partin Alan W
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
Urology 2008;72(2):396-400.
2008: Nielsen Matthew E; Makarov Danil V; Humphreys Elizabeth; Mangold Leslie; Partin Alan W; Walsh Patrick C
Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Urology 2008;72(2):389-93; discussion 394-5.
2008: Isharwal Sumit; Miller Michael C; Marlow Cameron; Makarov Danil V; Partin Alan W; Veltri Robert W
p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
The Prostate 2008;68(10):1097-104.
2008: Hernandez David J; Nielsen Matthew E; Han Misop; Trock Bruce J; Partin Alan W; Walsh Patrick C; Epstein Jonathan I
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
Urology 2008;72(1):172-6.
2008: Trock Bruce J; Han Misop; Freedland Stephen J; Humphreys Elizabeth B; DeWeese Theodore L; Partin Alan W; Walsh Patrick C
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
JAMA : the journal of the American Medical Association 2008;299(23):2760-9.
2008: Yoon Ghil Suk; Wang Wenle; Osunkoya Adeboye O; Lane Zhaoli; Partin Alan W; Epstein Jonathan I
Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
The Journal of urology 2008;179(6):2203-6; discussion 2206.
2008: Loeb Stacy; Hernandez David J; Mangold Leslie A; Humphreys Elizabeth B; Agro Marilyn; Walsh Patrick C; Partin Alan W; Han Misop
Progression after radical prostatectomy for men in their thirties compared to older men.
BJU international 2008;101(12):1503-6.
2008: Sun Jielin; Purcell Lina; Gao Zhengrong; Isaacs Sarah D; Wiley Kathleen E; Hsu Fang-Chi; Liu Wennuan; Duggan David; Carpten John D; Grönberg Henrik; Xu Jianfeng; Chang Bao-Li; Partin Alan W; Walsh Patrick C; Isaacs William B; Zheng S Lilly
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans.
The Prostate 2008;68(7):691-7.
2008: Magheli Ahmed; Rais-Bahrami Soroush; Trock Bruce J; Humphreys Elizabeth B; Partin Alan W; Han Misop; Gonzalgo Mark L
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
The Journal of urology 2008;179(5):1780-4; discussion 1784.
2008: Deras Ina L; Aubin Sheila M J; Blase Amy; Day John R; Koo Seongjoon; Partin Alan W; Ellis William J; Marks Leonard S; Fradet Yves; Rittenhouse Harry; Groskopf Jack
PCA3: a molecular urine assay for predicting prostate biopsy outcome.
The Journal of urology 2008;179(4):1587-92.
2008: Müntener Michael; Epstein Jonathan I; Hernandez David J; Gonzalgo Mark L; Mangold Leslie; Humphreys Elizabeth; Walsh Patrick C; Partin Alan W; Nielsen Matthew E
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
European urology 2008;53(4):767-75; discussion 775-6.
2008: Gudmundsson Julius; Sulem Patrick; Rafnar Thorunn; Bergthorsson Jon T; Manolescu Andrei; Gudbjartsson Daniel; Agnarsson Bjarni A; Sigurdsson Asgeir; Benediktsdottir Kristrun R; Blondal Thorarinn; Jakobsdottir Margret; Stacey Simon N; Kostic Jelena; Kristinsson Kari T; Birgisdottir Birgitta; Ghosh Shyamali; Magnusdottir Droplaug N; Thorlacius Steinunn; Thorleifsson Gudmar; Zheng S Lilly; Sun Jielin; Chang Bao-Li; Elmore J Bradford; Breyer Joan P; McReynolds Kate M; Bradley Kevin M; Yaspan Brian L; Wiklund Fredrik; Stattin Par; Lindström Sara; Adami Hans-Olov; McDonnell Shannon K; Schaid Daniel J; Cunningham Julie M; Wang Liang; Cerhan James R; St Sauver Jennifer L; Isaacs Sara D; Wiley Kathleen E; Partin Alan W; Walsh Patrick C; Polo Sonia; Ruiz-Echarri Manuel; Navarrete Sebastian; Fuertes Fernando; Saez Berta; Godino Javier; Weijerman Philip C; Swinkels Dorine W; Aben Katja K; Witjes J Alfred; Suarez Brian K; Helfand Brian T; Frigge Michael L; Kristjansson Kristleifur; Ober Carole; Jonsson Eirikur; Einarsson Gudmundur V; Xu Jianfeng; Gronberg Henrik; Smith Jeffrey R; Thibodeau Stephen N; Isaacs William B; Catalona William J; Mayordomo Jose I; Kiemeney Lambertus A; Barkardottir Rosa B; Gulcher Jeffrey R; Thorsteinsdottir Unnur; Kong Augustine; Stefansson Kari
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
Nature genetics 2008;40(3):281-3.
2008: Makarov Danil V; Marlow Cameron; Epstein Jonathan I; Miller M Craig; Landis Patricia; Partin Alan W; Carter H Ballentine; Veltri Robert W
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
The Prostate 2008;68(2):183-9.
2008: Bastian Patrick J; Palapattu Ganesh S; Yegnasubramanian Srinivasan; Rogers Craig G; Lin Xiaohui; Mangold Leslie A; Trock Bruce; Eisenberger Mario A; Partin Alan W; Nelson William G
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
The Journal of urology 2008;179(2):529-34; discussion 534-5.
2008: Veltri Robert W; Miller M Craig; Isharwal Sumit; Marlow Cameron; Makarov Danil V; Partin Alan W
Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(1):102-10.
2008: McLerran Dale; Grizzle William E; Feng Ziding; Thompson Ian M; Bigbee William L; Cazares Lisa H; Chan Daniel W; Dahlgren Jackie; Diaz Jose; Kagan Jacob; Lin Daniel W; Malik Gunjan; Oelschlager Denise; Partin Alan; Randolph Timothy W; Sokoll Lori; Srivastava Shiv; Srivastava Sudhir; Thornquist Mark; Troyer Dean; Wright George L; Zhang Zhen; Zhu Liu; Semmes O John
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
Clinical chemistry 2008;54(1):53-60.
2008: Makarov Danil V; Humphreys Elizabeth B; Mangold Leslie A; Carducci Michael A; Partin Alan W; Eisenberger Mario A; Walsh Patrick C; Trock Bruce J
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The Journal of urology 2008;179(1):156-61; discussion 161-2.
2008: McLerran Dale; Grizzle William E; Feng Ziding; Bigbee William L; Banez Lionel L; Cazares Lisa H; Chan Daniel W; Diaz Jose; Izbicka Elzbieta; Kagan Jacob; Malehorn David E; Malik Gunjan; Oelschlager Denise; Partin Alan; Randolph Timothy; Rosenzweig Nicole; Srivastava Shiv; Srivastava Sudhir; Thompson Ian M; Thornquist Mark; Troyer Dean; Yasui Yutaka; Zhang Zhen; Zhu Liu; Semmes O John
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
Clinical chemistry 2008;54(1):44-52.
2008: Loeb Stacy; Partin Alan W
Single nucleotide polymorphisms and prostate cancer susceptibility.
Reviews in urology 2008;10(4):304-5.
2008: Makarov Danil V; Partin Alan W
Weighing the risks: prostate cancer versus cardiovascular disease.
Reviews in urology 2008;10(2):171-3.
2008: Brawer Michael K; Makarov Danil V; Partin Alan W; Roehrborn Claus G; Nickel J Curtis; Lu Shing-Hwa; Yoshimura Naoki; Chancellor Michael B; Assimos Dean G
Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
Reviews in urology 2008;10(2):136-56.
2008: Makarov Danil V; Partin Alan W
Focal therapy for prostate cancer.
Reviews in urology 2008;10(1):81-2.
2007: Duggan David; Zheng Siqun L; Knowlton Michele; Benitez Debbie; Dimitrov Latchezar; Wiklund Fredrik; Robbins Christiane; Isaacs Sarah D; Cheng Yu; Li Ge; Sun Jielin; Chang Bao-Li; Marovich Leslie; Wiley Kathleen E; Bälter Katarina; Stattin Pär; Adami Hans-Olov; Gielzak Marta; Yan Guifang; Sauvageot Jurga; Liu Wennuan; Kim Jin Woo; Bleecker Eugene R; Meyers Deborah A; Trock Bruce J; Partin Alan W; Walsh Patrick C; Isaacs William B; Grönberg Henrik; Xu Jianfeng; Carpten John D
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
Journal of the National Cancer Institute 2007;99(24):1836-44.
2007: Hernandez David J; Nielsen Matthew E; Han Misop; Partin Alan W
Contemporary evaluation of the D'amico risk classification of prostate cancer.
Urology 2007;70(5):931-5.
2007: Bañez Lionel L; Hamilton Robert J; Partin Alan W; Vollmer Robin T; Sun Leon; Rodriguez Carmen; Wang Yiting; Terris Martha K; Aronson William J; Presti Joseph C; Kane Christopher J; Amling Christopher L; Moul Judd W; Freedland Stephen J
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.
JAMA : the journal of the American Medical Association 2007;298(19):2275-80.
2007: Zheng S Lilly; Sun Jielin; Cheng Yu; Li Ge; Hsu Fang-Chi; Zhu Yi; Chang Bao-Li; Liu Wennuan; Kim Jin Woo; Turner Aubrey R; Gielzak Marta; Yan Guifang; Isaacs Sarah D; Wiley Kathleen E; Sauvageot Jurga; Chen Huann-Sheng; Gurganus Robin; Mangold Leslie A; Trock Bruce J; Gronberg Henrik; Duggan David; Carpten John D; Partin Alan W; Walsh Patrick C; Xu Jianfeng; Isaacs William B
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
Journal of the National Cancer Institute 2007;99(20):1525-33.
2007: Malik Gunjan; Rojahn Elizabeth; Ward Michael D; Gretzer Mathew B; Partin Alan W; Semmes O John; Veltri Robert W
SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
The Prostate 2007;67(14):1565-75.
2007: Bastian Patrick J; Palapattu Ganesh S; Yegnasubramanian Srinivasan; Lin Xiaohui; Rogers Craig G; Mangold Leslie A; Trock Bruce; Eisenberger Mario; Partin Alan W; Nelson William G
Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5361-7.
2007: Collins Connie; Carducci Michael A; Eisenberger Mario A; Isaacs John T; Partin Alan W; Pili Roberto; Sinibaldi Victoria J; Walczak Janet S; Denmeade Samuel R
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: Djavan B; Marihart S; Kuehhas F; Rom M; Partin A; Schalken J; Sekeres T
[Resveratrol and newly synthetized resveratrol analogs in therapy of prostate carcinoma]
Der Urologe. Ausg. A 2007;46(9):1101-3.
2007: Veltri Robert W; Marlow Cameron; Khan Masood A; Miller Michael C; Epstein Jonathan I; Partin Alan W
Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis.
The Prostate 2007;67(11):1202-10.
2007: Mavropoulos John C; Partin Alan W; Amling Christopher L; Terris Martha K; Kane Christopher J; Aronson William J; Presti Joseph C; Mangold Leslie A; Freedland Stephen J
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?
Urology 2007;69(6):1138-42.
2007: Makarov Danil V; Trock Bruce J; Humphreys Elizabeth B; Mangold Leslie A; Walsh Patrick C; Epstein Jonathan I; Partin Alan W
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
Urology 2007;69(6):1095-101.
2007: Freedland Stephen J; Humphreys Elizabeth B; Mangold Leslie A; Eisenberger Mario; Dorey Frederick J; Walsh Patrick C; Partin Alan W
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1765-71.
2007: Kibel Adam S; Rosenbaum Eli; Kattan Michael W; Picus Joel; Dreicer Robert; Klein Eric A; Chatta Gurkamal S; Nelson Joel B; DiPaola Robert S; Roth Bruce J; Cookson Michael S; Wilding George; Jarrard David F; Beer Tomasz M; Ryan Christopher W; Petrylak Daniel P; Benson Mitchell C; Partin Alan W; Garrett-Mayer Elizabeth; Eisenberger Mario A
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
2007: Hansel D E; DeMarzo A M; Platz E A; Jadallah S; Hicks J; Epstein J I; Partin A W; Netto G J
Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
The Journal of urology 2007;177(5):1736-40.
2007: Gudmundsson Julius; Sulem Patrick; Manolescu Andrei; Amundadottir Laufey T; Gudbjartsson Daniel; Helgason Agnar; Rafnar Thorunn; Bergthorsson Jon T; Agnarsson Bjarni A; Baker Adam; Sigurdsson Asgeir; Benediktsdottir Kristrun R; Jakobsdottir Margret; Xu Jianfeng; Blondal Thorarinn; Kostic Jelena; Sun Jielin; Ghosh Shyamali; Stacey Simon N; Mouy Magali; Saemundsdottir Jona; Backman Valgerdur M; Kristjansson Kristleifur; Tres Alejandro; Partin Alan W; Albers-Akkers Marjo T; Godino-Ivan Marcos Javier; Walsh Patrick C; Swinkels Dorine W; Navarrete Sebastian; Isaacs Sarah D; Aben Katja K; Graif Theresa; Cashy John; Ruiz-Echarri Manuel; Wiley Kathleen E; Suarez Brian K; Witjes J Alfred; Frigge Mike; Ober Carole; Jonsson Eirikur; Einarsson Gudmundur V; Mayordomo Jose I; Kiemeney Lambertus A; Isaacs William B; Catalona William J; Barkardottir Rosa B; Gulcher Jeffrey R; Thorsteinsdottir Unnur; Kong Augustine; Stefansson Kari
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Nature genetics 2007;39(5):631-7.
2007: Leman Eddy S; Cannon Grant W; Trock Bruce J; Sokoll Lori J; Chan Daniel W; Mangold Leslie; Partin Alan W; Getzenberg Robert H
EPCA-2: a highly specific serum marker for prostate cancer.
Urology 2007;69(4):714-20.
2007: Parsons J Kellogg; Partin Alan W; Trock Bruce; Bruzek Debra J; Cheli Carol; Sokoll Lori J
Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy.
BJU international 2007;99(4):758-61.
2007: Freedland Stephen J; Partin Alan W; Humphreys Elizabeth B; Mangold Leslie A; Walsh Patrick C
Radical prostatectomy for clinical stage T3a disease.
Cancer 2007;109(7):1273-8.
2007: Shafer Michael W; Mangold Leslie; Partin Alan W; Haab Brian B
Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
The Prostate 2007;67(3):255-67.
2007: Brawer Michael K; Makarov Danil V; Partin Alan W; Roehrborn Claus G; Curtis Nickel J; Chancellor Michael B; Assimos Dean G; Shapiro Ellen; Rajfer Jacob
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.
Reviews in urology 2007;9(3):133-54.
2007: Makarov Danil V; Partin Alan W
Prostate-Cancer Risk Stratification via Early PSA Testing.
Reviews in urology 2007;9(2):91-2.
2007: Nielsen Matthew E; Partin Alan W
The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer.
Reviews in urology 2007;9(2):57-62.
2007: Makarov Danil V; Partin Alan W
Postprostatectomy risk stratification based on detection of occult lymph node metastasis.
Reviews in urology 2007;9(1):41-3.
2006: Marks Leonard S; Mazer Norman A; Mostaghel Elahe; Hess David L; Dorey Frederick J; Epstein Jonathan I; Veltri Robert W; Makarov Danil V; Partin Alan W; Bostwick David G; Macairan Maria Luz; Nelson Peter S
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2006;296(19):2351-61.
2006: Veltri Robert W; Khan Masood A; Marlow Cameron; Miller M Craig; Mikolajczyk Stephen D; Kojima Munekado; Partin Alan W; Marks Leonard S
Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer.
Urology 2006;68(4):898-904.
2006: Freedland Stephen J; Humphreys Elizabeth B; Mangold Leslie A; Eisenberger Mario; Partin Alan W
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
The Journal of urology 2006;176(4 Pt 1):1404-8.
2006: Bastian Patrick J; Gonzalgo Mark L; Aronson William J; Terris Martha K; Kane Christopher J; Amling Christopher L; Presti Joseph C; Mangold Leslie A; Humphreys Elizabeth; Epstein Jonathan I; Partin Alan W; Freedland Stephen J
Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Cancer 2006;107(6):1265-72.
2006: Makarov Danil V; Humphreys Elizabeth B; Mangold Leslie A; Walsh Patrick C; Partin Alan W; Epstein Jonathan I; Freedland Stephen J
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
The Journal of urology 2006;176(2):554-8.
2006: Nielsen Matthew E; Han Misop; Mangold Leslie; Humphreys Elizabeth; Walsh Patrick C; Partin Alan W; Freedland Stephen J
Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.
The Journal of urology 2006;176(2):515-9.
2006: Rohrmann Sabine; Fallin M Daniele; Page William F; Reed Terry; Partin Alan W; Walsh Patrick C; Platz Elizabeth A
Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins.
Epidemiology (Cambridge, Mass.) 2006;17(4):419-27.
2006: Parsons J Kellogg; Carter H Ballentine; Partin Alan W; Windham B Gwen; Metter E Jeffrey; Ferrucci Luigi; Landis Patricia; Platz Elizabeth A
Metabolic factors associated with benign prostatic hyperplasia.
The Journal of clinical endocrinology and metabolism 2006;91(7):2562-8.
2006: Parsons J Kellogg; Partin Alan W
Clinical interpretation of prostate biopsy reports.
Urology 2006;67(3):452-7.
2006: Freedland Stephen J; Partin Alan W
Prostate-specific antigen: update 2006.
Urology 2006;67(3):458-60.
2006: Rohrmann Sabine; Fallin M Daniele; Page William F; Reed Terry; Partin Alan W; Walsh Patrick C; Platz Elizabeth A
Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry".
International journal of cancer. Journal international du cancer 2006;118(3):785.
2006: Gonzalgo Mark L; Bastian Patrick J; Mangold Leslie A; Trock Bruce J; Epstein Jonathan I; Walsh Patrick C; Partin Alan W
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
Urology 2006;67(1):115-9.
2006: Makarov Danil V; Partin Alan W
Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate.
Reviews in urology 2006;8(4):232-4.
2006: Allaf Mohamad E; Partin Alan W; Carter H Ballentine
The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.
Reviews in urology 2006;8(3):112-9.
2006: Makarov Danil V; Partin Alan W
Translation research in prostate cancer.
Reviews in urology 2006;8(2):89-91.
2006: Makarov Danil V; Partin Alan W
The predictive capability of prostate-specific antigen kinetics.
Reviews in urology 2006;8(1):41-3.
2005: Rosenbaum Eli; Hoque Mohammad Obaidul; Cohen Yoram; Zahurak Marianna; Eisenberger Mario A; Epstein Jonathan I; Partin Alan W; Sidransky David
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8321-5.
2005: Wu Christopher L; Rowlingson Andrew J; Partin Alan W; Kalish Murray A; Courpas Genevieve E; Walsh Patrick C; Fleisher Lee A
Correlation of postoperative pain to quality of recovery in the immediate postoperative period.
Regional anesthesia and pain medicine 2005;30(6):516-22.
2005: Parsons J Kellogg; Partin Alan W
Hugh Hampton Young, benign prostatic hyperplasia, and "the cure of prostatic obstruction".
Journal of the American College of Surgeons 2005;201(5):654-5.
2005: Freedland Stephen J; Grubb Kelly A; Yiu Sindy K; Nielsen Matthew E; Mangold Leslie A; Isaacs William B; Epstein Jonathan I; Partin Alan W
Obesity and capsular incision at the time of open retropubic radical prostatectomy.
The Journal of urology 2005;174(5):1798-801; discussion 1801.
2005: Freedland Stephen J; Mangold Leslie A; Walsh Patrick C; Partin Alan W
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1276-81; discussion 1281; author reply 1281.
2005: Freedland Stephen J; Sokoll Lori J; Platz Elizabeth A; Mangold Leslie A; Bruzek Debra J; Mohr Phaedre; Yiu Sindy K; Partin Alan W
Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.
The Journal of urology 2005;174(4 Pt 1):1266-70.
2005: Truskinovsky Alexander M; Partin Alan W; Kroll Martin H
Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen.
Urology 2005;66(3):577-81.
2005: Freedland Stephen J; Grubb Kelly A; Yiu Sindy K; Humphreys Elizabeth B; Nielsen Matthew E; Mangold Leslie A; Isaacs William B; Partin Alan W
Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
The Journal of urology 2005;174(3):919-22.
2005: Wu Christopher L; Partin Alan W; Rowlingson Andrew J; Kalish Murray A; Walsh Patrick C; Fleisher Lee A
Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy.
Urology 2005;66(2):366-70.
2005: Freedland Stephen J; Humphreys Elizabeth B; Mangold Leslie A; Eisenberger Mario; Dorey Frederick J; Walsh Patrick C; Partin Alan W
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
JAMA : the journal of the American Medical Association 2005;294(4):433-9.
2005: Bastian Patrick J; Palapattu Ganesh S; Lin Xiaohui; Yegnasubramanian Srinivasan; Mangold Leslie A; Trock Bruce; Eisenberger Mario A; Partin Alan W; Nelson William G
Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4037-43.
2005: Ellison L M; Trock B J; Poe N R; Partin A W
The effect of hospital volume on cancer control after radical prostatectomy.
The Journal of urology 2005;173(6):2094-8.
2005: Freedland Stephen J; Isaacs William B; Mangold Leslie A; Yiu Sindy K; Grubb Kelly A; Partin Alan W; Epstein Jonathan I; Walsh Patrick C; Platz Elizabeth A
Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2883-8.
2005: Freedland Stephen J; Sokoll Lori J; Mangold Leslie A; Bruzek Debra J; Mohr Phaedre; Yiu Sindy K; Epstein Jonathan I; Partin Alan W
Serum leptin and pathological findings at the time of radical prostatectomy.
The Journal of urology 2005;173(3):773-6.
2005: Haese Alexander; Vaisanen Ville; Lilja Hans; Kattan Michael W; Rittenhouse Harry G; Pettersson Kim; Chan Daniel W; Huland Hartwig; Sokoll Lori J; Partin Alan W
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
The Journal of urology 2005;173(3):752-6.
2005: Khan Masood A; Partin Alan W
Surgical margin status after radical retropubic prostatectomy.
BJU international 2005;95(3):281-4.
2005: Semmes O John; Feng Ziding; Adam Bao-Ling; Banez Lionel L; Bigbee William L; Campos David; Cazares Lisa H; Chan Daniel W; Grizzle William E; Izbicka Elzbieta; Kagan Jacob; Malik Gunjan; McLerran Dale; Moul Judd W; Partin Alan; Prasanna Premkala; Rosenzweig Jason; Sokoll Lori J; Srivastava Shiv; Srivastava Sudhir; Thompson Ian; Welsh Manda J; White Nicole; Winget Marcy; Yasui Yutaka; Zhang Zhen; Zhu Liu
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
Clinical chemistry 2005;51(1):102-12.
2005: Freedland Stephen J; Partin Alan W
Detecting Prostate Cancer with Molecular Markers: uPM3.
Reviews in urology 2005;7(4):236-8.
2005: Freedland Stephen J; Partin Alan W
Early hormonal therapy for prostate cancer: the good, the bad, and the ugly.
Reviews in urology 2005;7(3):187-9.
2005: Freedland Stephen J; Partin Alan W
Dawning of the age of chemotherapy for prostate cancer.
Reviews in urology 2005;7(2):110-2.
2005: Freedland Stephen J; Partin Alan W
Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy.
Reviews in urology 2005;7(1):46-7.
2005: Freedland Stephen J; Partin Alan W
Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004.
Reviews in urology 2005;7(1):41-5.
2005: Khan M A; Partin A W
Expectant management: an option for localized prostate cancer.
Prostate cancer and prostatic diseases 2005;8(4):311-5.
2004: Khan Masood A; Carducci Michael A; Partin Alan W
Docetaxel in androgen-independent prostate cancer: an update.
BJU international 2004;94(9):1209-10.
2004: Khan Masood A; Sokoll Lori J; Chan Daniel W; Mangold Leslie A; Mohr Phaedre; Mikolajczyk Stephen D; Linton Harry J; Evans Cindy L; Rittenhouse Harry G; Partin Alan W
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Urology 2004;64(6):1160-4.
2004: Rogers Craig G; Khan Masood A; Craig Miller M; Veltri Robert W; Partin Alan W
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Cancer 2004;101(11):2549-56.
2004: Khan Masood A; Mangold Leslie A; Epstein Jonathan I; Boitnott John K; Walsh Patrick C; Partin Alan W
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer.
The Journal of urology 2004;172(5 Pt 1):1835-9.
2004: Bastian Patrick J; Mangold Leslie A; Epstein Jonathan I; Partin Alan W
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
Cancer 2004;101(9):2001-5.
2004: Faith Dennis A; Isaacs William B; Morgan James D; Fedor Helen L; Hicks Jessica L; Mangold Leslie A; Walsh Patrick C; Partin Alan W; Platz Elizabeth A; Luo Jun; De Marzo Angelo M
Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.
The Prostate 2004;61(3):215-27.
2004: Marks Leonard S; Kojima Munekado; Demarzo Angelo; Heber David; Bostwick David G; Qian Junqi; Dorey Frederick J; Veltri Robert W; Mohler James L; Partin Alan W
Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue.
Urology 2004;64(4):765-71.
2004: Aydin Hakan; Tsuzuki Toyonori; Hernandez David; Walsh Patrick C; Partin Alan W; Epstein Jonathan I
Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression.
Urology 2004;64(3):551-5.
2004: Gretzer M B; Chan D W; van Rootselaar C L; Rosenzweig J M; Dalrymple S; Mangold L A; Partin A W; Veltri R W
Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
The Prostate 2004;60(4):325-31.
2004: Eisenberger Mario; Partin Alan
Progress toward identifying aggressive prostate cancer.
The New England journal of medicine 2004;351(2):180-1.
2004: Parsons J Kellogg; Brawer Michael K; Cheli Carol D; Partin Alan W; Djavan Robert
Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
BJU international 2004;94(1):47-50.
2004: Khan Masood A; Partin Alan W
Management of patients with an increasing prostate-specific antigen after radical prostatectomy.
Current urology reports 2004;5(3):179-87.
2004: Veltri Robert W; Khan Masood A; Miller M Craig; Epstein Jonathan I; Mangold Leslie A; Walsh Patrick C; Partin Alan W
Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3465-73.
2004: Freedland Stephen J; Mangold Leslie A; Epstein Jonathan I; Partin Alan W
Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Urology 2004;63(5):887-91.
2004: Parsons J Kellogg; Partin Alan W
Applying complexed prostate-specific antigen to clinical practice.
Urology 2004;63(5):815-8.
2004: Li Jinong; White Nicole; Zhang Zhen; Rosenzweig Jason; Mangold Leslie A; Partin Alan W; Chan Daniel W
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.
The Journal of urology 2004;171(5):1782-7.
2004: Freedland Stephen J; Partin Alan W; Epstein Jonathan I; Walsh Patrick C
Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Cancer 2004;100(8):1646-9.
2004: Trock Bruce J; Brotzman Michelle; Utz William J; Ugarte Roland R; Kaplan Steven A; Larson Thayne R; Blute Michael L; Roehrborn Claus G; Partin Alan W
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Urology 2004;63(4):716-21.
2004: Han Misop; Partin Alan W; Chan David Y; Walsh Patrick C
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series.
The Journal of urology 2004;171(1):23-6.
2004: Freedland Stephen J; Partin Alan W
Obesity and prostate cancer detection and progression.
Reviews in urology 2004;6(4):214-6.
2004: Khan Masood A; Partin Alan W
Prostate cancer and chemotherapy.
Reviews in urology 2004;6(3):167-9.
2004: Khan Masood A; Partin Alan W
Finasteride and prostate cancer.
Reviews in urology 2004;6(2):97-8.
2004: Khan Masood A; Partin Alan W
Vitamin d for the management of prostate cancer.
Reviews in urology 2004;6(2):95-7.
2004: Khan Masood A; Partin Alan W
Endothelin-a receptor antagonists and advanced prostate cancer.
Reviews in urology 2004;6(1):47-8.
2004: Khan Masood A; Partin Alan W
Vasectomy and prostate cancer.
Reviews in urology 2004;6(1):46-7.
2004: Khan Masood A; Partin Alan W
Tissue microarrays in prostate cancer research.
Reviews in urology 2004;6(1):44-6.
2004: Veltri R W; Park J; Miller M C; Marks L; Kojima M; van Rootselaar C; Khan M A; Partin A W
Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men.
Prostate cancer and prostatic diseases 2004;7(3):232-7.
2003: Park Jae; Sokoll Lori J; Bruzek Debra J; Mangold Leslie; Gurganus Robin; Khan Masood A; Partin Alan W; Chan Daniel W; Veltri Robert W
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.
Clinical prostate cancer 2003;2(3):173-6.
2003: Cannon Glenn M; Walsh Patrick C; Partin Alan W; Pound Charles R
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer.
Urology 2003;62 Suppl 1():2-8.
2003: Khan Masood A; Walsh Patrick C; Miller M Craig; Bales Wesley D; Epstein Jonathan I; Mangold Leslie A; Partin Alan W; Veltri Robert W
Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Cancer 2003;98(12):2583-91.
2003: Naya Yoshio; Fritsche Herbert A; Cheli Carol D; Stamey Thomas A; Bartsch Georg; Brawer Michael K; Childs Stacy; Taneja Samir S; Lepor Herbert; Partin Alan W; Sokoll Lori J; Chan Daniel W; Babaian Richard J
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
Urology 2003;62(6):1058-62.
2003: Khan Masood A; Carter H Ballentine; Epstein Jonathan I; Miller Michael C; Landis Patricia; Walsh Patrick W; Partin Alan W; Veltri Robert W
Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
The Journal of urology 2003;170(6 Pt 1):2274-8.
2003: Gretzer Matthew B; Partin Alan W
PSA markers in prostate cancer detection.
The Urologic clinics of North America 2003;30(4):677-86.
2003: Khan Masood A; Partin Alan W; Mangold Leslie A; Epstein Jonathan I; Walsh Patrick C
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
Urology 2003;62(5):866-71.
2003: Khan Masood A; Partin Alan W; Carter H Ballentine
Expectant management of localized prostate cancer.
Urology 2003;62(5):793-9.
2003: Bouwman Kerri; Qiu Ji; Zhou Heping; Schotanus Mark; Mangold Leslie A; Vogt Robert; Erlandson Erik; Trenkle John; Partin Alan W; Misek David; Omenn Gilbert S; Haab Brian B; Hanash Samir
Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity.
Proteomics 2003;3(11):2200-7.
2003: Kalra Pankaj; Togami Joanna; Bansal B S Gaurav; Partin Alan W; Brawer Michael K; Babaian Richard J; Ross Lawrence S; Niederberger Craig S
A neurocomputational model for prostate carcinoma detection.
Cancer 2003;98(9):1849-54.
2003: Partin Alan W; Brawer Michael K; Bartsch Georg; Horninger Wolfgang; Taneja Samir S; Lepor Herbert; Babaian Richard; Childs Stacy J; Stamey Thomas; Fritsche Herbert A; Sokoll Lori; Chan Daniel W; Thiel Robert P; Cheli Carol D
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
The Journal of urology 2003;170(5):1787-91.
2003: Khan Masood A; Carducci Michael A; Partin Alan W
The evolving role of docetaxel in the management of androgen independent prostate cancer.
The Journal of urology 2003;170(5):1709-16.
2003: Khan Masood A; Partin Alan W; Rittenhouse Harry G; Mikolajczyk Stephen D; Sokoll Lori J; Chan Daniel W; Veltri Robert W
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
The Journal of urology 2003;170(3):723-6.
2003: Chan Theresa Y; Mikolajczyk Stephen D; Lecksell Kristin; Shue Matthew J; Rittenhouse Harry G; Partin Alan W; Epstein Jonathan I
Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
Urology 2003;62(1):177-81.
2003: Khan Masood A; Han Misop; Partin Alan W; Epstein Jonathan I; Walsh Patrick C
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.
Urology 2003;62(1):86-91; discussion 91-2.
2003: Khan M A; Partin A W
Partin tables: past and present.
BJU international 2003;92(1):7-11.
2003: Hlavaty John J; Partin Alan W; Shue Matthew J; Mangold Leslie A; Derby Jennifer; Javier Teofilo; Kelley Shane; Stieg Adam; Briggman Joseph V; Hass G Michael; Wu Ying-Jye
Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer.
Urology 2003;61(6):1261-5.
2003: Haese Alexander; Vaisanen Ville; Finlay Judith A; Pettersson Kim; Rittenhouse Harry G; Partin Alan W; Bruzek Debra J; Sokoll Lori J; Lilja Hans; Chan Daniel W
Standardization of two immunoassays for human glandular kallikrein 2.
Clinical chemistry 2003;49(4):601-10.
2003: Sokoll Lori J; Chan Daniel W; Mikolajczyk Stephen D; Rittenhouse Harry G; Evans Cindy L; Linton Harry J; Mangold Leslie A; Mohr Phaedre; Bartsch Georg; Klocker Helmut; Horninger Wolfgang; Partin Alan W
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Urology 2003;61(2):274-6.
2003: Haese Alexander; Chaudhari Manisha; Miller M Craig; Epstein Jonathan I; Huland Hartwig; Palisaar Juri; Graefen Markus; Hammerer Peter; Poole Edward C; O'Dowd Gerard J; Partin Alan W; Veltri Robert W
Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Cancer 2003;97(4):969-78.
2003: Han Misop; Partin Alan W; Zahurak Marianna; Piantadosi Steven; Epstein Johnathan I; Walsh Patrick C
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
The Journal of urology 2003;169(2):517-23.
2003: Babaian Richard J; Partin Alan W;
Prostate cancer early detection clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1 Suppl 1():S42-55.
2003: Khan Masood A; Partin Alan W
Expectant management of prostate cancer.
Reviews in urology 2003;5(4):247-50.
2003: Khan Masood A; Partin Alan W
Bisphosphonates in metastatic prostate cancer.
Reviews in urology 2003;5(3):204-6.
2003: Gretzer Matthew B; Partin Alan W
Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002.
Reviews in urology 2003;5(2):111-7.
2003: Gretzer Matthew B; Partin Alan W; Chan Daniel W; Veltri Robert W
Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).
Reviews in urology 2003;5(2):81-9.
2003: Khan Masood A; Partin Alan W
Chemoprevention and prostate cancer.
Reviews in urology 2003;5(1):61-3.
2003: Gretzer Matthew B; Partin Alan W
54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Reviews in urology 2003;5(1):45-8.
2003: Khan Masood A; Partin Alan W
Management of high-risk populations with locally advanced prostate cancer.
The oncologist 2003;8(3):259-69.
2002: Heath Elisabeth I; DeWeese Theodore L; Partin Alan W; De Marzo Angelo M; Groopman John D; Nelson William G; Piantadosi Steven A; Lieberman Ron; Carducci Michael A
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Clinical prostate cancer 2002;1(3):182-7.
2002: Gretzer Matthew B; Epstein Jonathan I; Pound Charles R; Walsh Patrick C; Partin Alan W
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Urology 2002;60(6):1034-9.
2002: Veltri Robert W; Marks Leonard S; Miller M Craig; Bales Wes D; Fan John; Macairan Maria Luz; Epstein Jonathan I; Partin Alan W
Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism.
Urology 2002;60(4):617-22.
2002: Veltri Robert W; Miller M Craig; O'dowd Gerard J; Partin Alan W
Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.
Urology 2002;60(4 Suppl 1):47-52.
2002: Ellison Lars; Cheli Carol D; Bright Steven; Veltri Robert W; Partin Alan W
Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
Urology 2002;60(4 Suppl 1):42-6.
2002: Naya Yoshio; Stamey Thomas A; Cheli Carol D; Partin Alan W; Sokoll Lori J; Chan Daniel W; Brawer Michael K; Taneja Samir S; Lepor Herbert; Bartsch Georg; Childs Stacy; Fritsche Herbert A; Babaian Richard J
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Urology 2002;60(4 Suppl 1):36-41.
2002: Horninger Wolfgang; Cheli Carol D; Babaian Richard J; Fritsche Herbert A; Lepor Herbert; Taneja Samir S; Childs Stacy; Stamey Thomas A; Sokoll Lori J; Chan Daniel W; Brawer Michael K; Partin Alan W; Bartsch Georg
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Urology 2002;60(4 Suppl 1):31-5.
2002: Sokoll Lori J; Bruzek Debra J; Dua Renu; Dunn Willard; Mohr Phaedre; Wallerson Gail; Eisenberger Mario; Partin Alan W; Chan Daniel W
Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.
Urology 2002;60(4 Suppl 1):24-30.
2002: Sokoll Lori J; Mangold Leslie A; Partin Alan W; Epstein Jonathan I; Bruzek Debra J; Dunn Willard; Mohr Phaedre; Wallerson Gail; Chan Daniel W
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Urology 2002;60(4 Suppl 1):18-23.
2002: Taneja Samir S; Hsu Elias I; Cheli Carol D; Walden Paul; Bartsch Georg; Horninger Wolfgang; Babaian Richard J; Fritsche Herbert A; Childs Stacy; Stamey Thomas A; Sokoll Lori J; Chan Daniel W; Brawer Michael K; Partin Alan W; Lepor Herbert
Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
Urology 2002;60(4 Suppl 1):10-7.
2002: Veltri Robert W; Chaudhari Manisha; Miller M Craig; Poole Edward C; O'Dowd Gerard J; Partin Alan W
Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage.
Clinical chemistry 2002;48(10):1828-34.
2002: Xu Jianfeng; Zheng S Lilly; Komiya Akira; Mychaleckyj Josyf C; Isaacs Sarah D; Hu Jennifer J; Sterling David; Lange Ethan M; Hawkins Gregory A; Turner Aubrey; Ewing Charles M; Faith Dennis A; Johnson Jill R; Suzuki Hiroyoshi; Bujnovszky Piroska; Wiley Kathleen E; DeMarzo Angelo M; Bova G Steven; Chang Baoli; Hall M Craig; McCullough David L; Partin Alan W; Kassabian Vahan S; Carpten John D; Bailey-Wilson Joan E; Trent Jeffrey M; Ohar Jill; Bleecker Eugene R; Walsh Patrick C; Isaacs William B; Meyers Deborah A
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
Nature genetics 2002;32(2):321-5.
2002: Partin Alan W; Hanks Gerald E; Klein Eric A; Moul Judd W; Nelson William G; Scher Howard I
Prostate-specific antigen as a marker of disease activity in prostate cancer.
Oncology (Williston Park, N.Y.) 2002;16(9):1218-24; discussion 1224, 1227-8 passim.
2002: Haese Alexander; Epstein Jonathan I; Huland Hartwig; Partin Alan W
Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma.
Cancer 2002;95(5):1016-21.
2002: Viglione Michael P; Potter Stephen; Partin Alan W; Lesniak Maciej S; Epstein Jonathan I
Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy?
Human pathology 2002;33(8):796-800.
2002: Partin Alan W; Hanks Gerald E; Klein Eric A; Moul Judd W; Nelson William G; Scher Howard I
Prostate-specific antigen as a marker of disease activity in prostate cancer.
Oncology (Williston Park, N.Y.) 2002;16(8):1024-38, 1042; discussion 1042, 1047-8, 1051.
2002: Haese Alexander; Dworschack Robert T; Partin Alan W
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
The Journal of urology 2002;168(2):504-8.
2002: Veltri Robert W; Miller M Craig; Mangold Leslie A; O'Dowd Gerard J; Epstein Jonathan I; Partin Alan W
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
The Journal of urology 2002;168(1):100-4.
2002: Mikolajczyk Stephen D; Marks Leonard S; Partin Alan W; Rittenhouse Harry G
Free prostate-specific antigen in serum is becoming more complex.
Urology 2002;59(6):797-802.
2002: Haese Alexander; Dworschack Robert T; Piccoli Steven P; Sokoll Lori J; Partin Alan W; Chan Daniel W
Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems.
Clinical chemistry 2002;48(6 Pt 1):944-7.
2002: Wright E James; Fang Junyong; Metter E Jeffrey; Partin Alan W; Landis Patricia; Chan Daniel W; Carter H Ballentine
Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.
The Journal of urology 2002;167(6):2484-7; discussion 2487-8.
2002: Makarov Danil V; Sanderson Harriete; Partin Alan W; Epstein Jonathan I
Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
The Journal of urology 2002;167(6):2440-2.
2002: Han Misop; Partin Alan W
Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy.
Seminars in urologic oncology 2002;20(2):123-30.
2002: Okihara Koji; Cheli Carol D; Partin Alan W; Fritche Herbert A; Chan Daniel W; Sokoll Lori J; Brawer Michael K; Schwartz Morton K; Vessella Robert L; Loughlin Kevin R; Johnston Dennis A; Babaian R Joseph
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
The Journal of urology 2002;167(5):2017-23; discussion 2023-4.
2002: Raj Ganesh V; Partin Alan W; Polascik Thomas J
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Cancer 2002;94(4):987-96.
2002: O'Malley Kiaran J; Pound Charles R; Walsh Patrick C; Epstein Jonathan I; Partin Alan W
Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy.
Urology 2002;59(1):85-90.
2002: Khan Masood A; Partin Alan W
Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer.
Reviews in urology 2002;4(4):198-200.
2002: Partin Alan W
High-grade prostatic intraepithelial neoplasia on a prostate biopsy-what does it mean?
Reviews in urology 2002;4(3):157-8.
2002: Sommerfeld Hans Jörg; Partin Alan Wayne; Pannek Jürgen
Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohistochemical study.
International urology and nephrology 2002;34(3):357-60.
2001: Partin A W; Mangold L A; Lamm D M; Walsh P C; Epstein J I; Pearson J D
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology 2001;58(6):843-8.
2001: Barocas D A; Han M; Epstein J I; Chan D Y; Trock B J; Walsh P C; Partin A W
Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?
Urology 2001;58(5):746-51.
2001: Partin A W
Letter from the editor.
Urology 2001;58(3):307-9.
2001: Goluboff E T; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein I B; Partin A W; Olsson C A;
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
The Journal of urology 2001;166(3):882-6.
2001: Han M; Partin A W; Pound C R; Epstein J I; Walsh P C
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.
The Urologic clinics of North America 2001;28(3):555-65.
2001: Feneley M R; Partin A W
Indicators of pathologic stage of prostate cancer and their use in clinical practice.
The Urologic clinics of North America 2001;28(3):443-58.
2001: Han M; Partin A W; Piantadosi S; Epstein J I; Walsh P C
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
The Journal of urology 2001;166(2):416-9.
2001: Veltri R W; Miller M C; Partin A W; Poole E C; O'Dowd G J
Prediction of prostate carcinoma stage by quantitative biopsy pathology.
Cancer 2001;91(12):2322-8.
2001: Miller M C; O'Dowd G J; Partin A W; Veltri R W
Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Urology 2001;57(6):1105-11.
2001: Potter S R; Horniger W; Tinzl M; Bartsch G; Partin A W
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
Urology 2001;57(6):1100-4.
2001: Roberts W W; Bergstralh E J; Blute M L; Slezak J M; Carducci M; Han M; Epstein J I; Eisenberger M A; Walsh P C; Partin A W
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.
Urology 2001;57(6):1033-7.
2001: Horninger W; Bartsch G; Snow P B; Brandt J M; Partin A W
The problem of cutoff levels in a screened population: appropriateness of informing screenees about their risk of having prostate carcinoma.
Cancer 2001;91(8 Suppl):1667-72.
2001: Han M; Snow P B; Brandt J M; Partin A W
Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma.
Cancer 2001;91(8 Suppl):1661-6.
2001: Han M; Piantadosi S; Zahurak M L; Sokoll L J; Chan D W; Epstein J I; Walsh P C; Partin A W
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.
Urology 2001;57(4):707-11.
2001: Marks L S; Epstein J I; Partin A W
The role of prostate needle biopsy in evaluation of chemopreventive agents.
Urology 2001;57(4 Suppl 1):191-3.
2001: Partin A W; Marks L S
Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents.
Urology 2001;57(4 Suppl 1):132-6.
2001: Sakr W A; Partin A W
Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia.
Urology 2001;57(4 Suppl 1):115-20.
2001: Lieberman R; Nelson W G; Sakr W A; Meyskens F L; Klein E A; Wilding G; Partin A W; Lee J J; Lippman S M
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Urology 2001;57(4 Suppl 1):4-27.
2001: Batuello J T; Gamito E J; Crawford E D; Han M; Partin A W; McLeod D G; ODonnell C
Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.
Urology 2001;57(3):481-5.
2001: Han M; Pound C R; Potter S R; Partin A W; Epstein J I; Walsh P C
Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications.
The Journal of urology 2001;165(3):864-6.
2001: Pannek J; Lecksell K L; Partin A W
Expression of metallothionein in seminal vesicles--an immunohistochemical study.
Scandinavian journal of urology and nephrology 2001;35(1):11-4.
2001: Han M; Partin A W
Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356).
Reviews in urology 2001;3(4):165-71.
2001: Partin A W
Cyclooxygenase-2 as a marker for prostate cancer.
Reviews in urology 2001;3(2):107-8.
2001: Pound C R; Brawer M K; Partin A W
Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.
Reviews in urology 2001;3(2):72-84.
2000: Partin A W
Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer?
Current urology reports 2000;1(4):245.
2000: Simon I; Snow P B; Marks L S; Christens-Barry W A; Epstein J I; Bluemke D A; Partin A W
Neural network prediction of prostate tissue composition based on magnetic resonance imaging analysis. A pilot study.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2000;22(6):445-52.
2000: Potter S R; Mangold L A; Shue M J; Taylor D C; Lecksell K L; Epstein J I; Walsh P C; Partin A W
Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
Cancer 2000;89(12):2577-86.
2000: Han M; Snow P B; Epstein J I; Chan T Y; Jones K A; Walsh P C; Partin A W
A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy.
Urology 2000;56(6):994-9.
2000: Chan T Y; Partin A W; Walsh P C; Epstein J I
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
Urology 2000;56(5):823-7.
2000: Blute M L; Bergstralh E J; Partin A W; Walsh P C; Kattan M W; Scardino P T; Montie J E; Pearson J D; Slezak J M; Zincke H
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
The Journal of urology 2000;164(5):1591-5.
2000: Epstein J I; Partin A W; Potter S R; Walsh P C
Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters.
Urology 2000;56(2):283-8.
2000: Catalona W J; Southwick P C; Slawin K M; Partin A W; Brawer M K; Flanigan R C; Patel A; Richie J P; Walsh P C; Scardino P T; Lange P H; Gasior G H; Loveland K G; Bray K R
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
Urology 2000;56(2):255-60.
2000: Feneley M R; Partin A W
Diagnosis of localized prostate cancer: 10 years of progress.
Current opinion in urology 2000;10(4):319-27.
2000: Han M; Walsh P C; Partin A W; Rodriguez R
Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
The Journal of urology 2000;164(1):89-92.
2000: Reckwitz T; Potter S R; Partin A W
Prediction of locoregional extension and metastatic disease in prostate cancer: a review.
World journal of urology 2000;18(3):165-72.
2000: Wang Z P; Eisenberger M A; Carducci M A; Partin A W; Scher H I; Ts'o P O
Identification and characterization of circulating prostate carcinoma cells.
Cancer 2000;88(12):2787-95.
2000: Vessella R L; Lange P H; Partin A W; Chan D W; Sokoll L J; Sasse E A; Crawford E D
Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
Urology 2000;55(6):909-14.
2000: Weir E G; Partin A W; Epstein J I
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
The Journal of urology 2000;163(6):1739-42.
2000: Han M; Potter S R; Partin A W
The role of free prostate-specific antigen in prostate cancer detection.
Current urology reports 2000;1(1):78-82.
2000: Pound C R; Partin A W
What does prostate-specific antigen recurrence mean?
Current urology reports 2000;1(1):28-35.
2000: Ripple M G; Potter S R; Partin A W; Epstein J I
Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2000;13(5):521-7.
2000: Crawford E D; Batuello J T; Snow P; Gamito E J; McLeod D G; Partin A W; Stone N; Montie J; Stock R; Lynch J; Brandt J
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.
Cancer 2000;88(9):2105-9.
2000: Brawer M K; Cheli C D; Neaman I E; Goldblatt J; Smith C; Schwartz M K; Bruzek D J; Morris D L; Sokoll L J; Chan D W; Yeung K K; Partin A W; Allard W J
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
The Journal of urology 2000;163(5):1476-80.
2000: Marks L S; Partin A W; Epstein J I; Tyler V E; Simon I; Macairan M L; Chan T L; Dorey F J; Garris J B; Veltri R W; Santos P B; Stonebrook K A; deKernion J B
Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
The Journal of urology 2000;163(5):1451-6.
2000: Pan C C; Potter S R; Partin A W; Epstein J I
The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system.
The American journal of surgical pathology 2000;24(4):563-9.
2000: Catalona W J; Partin A W; Slawin K M; Naughton C K; Brawer M K; Flanigan R C; Richie J P; Patel A; Walsh P C; Scardino P T; Lange P H; deKernion J B; Southwick P C; Loveland K G; Parson R E; Gasior G H
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
Urology 2000;55(3):372-6.
2000: LaFontaine P; Chan D; Partin A W; Gurganus R; Hortopan S C; Marshall F F
Minilaparotomy radical retropubic prostatectomy: updated technique and results.
Seminars in urologic oncology 2000;18(1):19-27.
2000: Partin A W; Murphy G P; Brawer M K
Report on Prostate Cancer Tumor Marker Workshop 1999.
Cancer 2000;88(4):955-63.
2000: Djavan B; Partin A W; Hoey M F; Roehrborn C G; Dixon C M; Marberger M
Transurethral radiofrequency therapy for benign prostatic hyperplasia using a novel saline-liquid conductor: the virtual electrode.
Urology 2000;55(1):13-6.
2000: Potter S R; Epstein J I; Partin A W
Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications.
Reviews in urology 2000;2(3):190-5.
2000: Potter S R; Partin A W
Tumor markers: an update on human kallikrein 2.
Reviews in urology 2000;2(4):221-2.
2000: Potter S R; Partin A W
The significance of perineural invasion found on needle biopsy of the prostate: implications for definitive therapy.
Reviews in urology 2000;2(2):87-90.
2000: Potter S R; Partin A W
Hereditary and familial prostate cancer: biologic aggressiveness and recurrence.
Reviews in urology 2000;2(1):35-6.
2000: Veltri R W; Partin A W; Miller M C
Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.
Journal of cellular biochemistry. Supplement 2000;Suppl 35():151-7.
2000: Nelson W G; Simons J W; Mikhak B; Chang J F; DeMarzo A M; Carducci M A; Kim M; Weber C E; Baccala A A; Goeman M A; Clift S M; Ando D G; Levitsky H I; Cohen L K; Sanda M G; Mulligan R C; Partin A W; Carter H B; Piantadosi S; Marshall F F
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S67-72.
1999: Wang T J; Linton H J; Payne J; Rittenhouse H G; Chan D W; Partin A W; Wolfert R L; Kuus-Reichel K
Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
Hybridoma 1999;18(6):535-41.
1999: Lemkin P F; Myrick J M; Lakshmanan Y; Shue M J; Patrick J L; Hornbeck P V; Thornwal G C; Partin A W
Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet-WebGel.
Electrophoresis 1999;20(18):3492-507.
1999: Manyak M J; Hinkle G H; Olsen J O; Chiaccherini R P; Partin A W; Piantadosi S; Burgers J K; Texter J H; Neal C E; Libertino J A; Wright G L; Maguire R T
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Urology 1999;54(6):1058-63.
1999: Hurwitz M D; DeWeese T L; Zinreich E S; Epstein J I; Partin A W
Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
International journal of cancer. Journal international du cancer 1999;84(6):594-7.
1999: Pannek J; Lakshmanan Y; Pound C R; Lemkin P F; Epstein J I; Partin A W
Nuclear shape and nuclear matrix protein composition in prostate and seminal vesicles.
Urology 1999;54(5):934-9.
1999: Partin A W; Catalona W J; Finlay J A; Darte C; Tindall D J; Young C Y; Klee G G; Chan D W; Rittenhouse H G; Wolfert R L; Woodrum D L
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Urology 1999;54(5):839-45.
1999: Potter S R; Miller M C; Mangold L A; Jones K A; Epstein J I; Veltri R W; Partin A W
Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.
Urology 1999;54(5):791-5.
1999: Potter S R; Partin A W
Prostate cancer: detection, staging, and treatment of localized disease.
Seminars in roentgenology 1999;34(4):269-83.
1999: Potter S R; Partin A W
Prostatitis syndromes and benign prostatic hyperplasia.
Seminars in roentgenology 1999;34(4):256-68.
1999: Simons J W; Mikhak B; Chang J F; DeMarzo A M; Carducci M A; Lim M; Weber C E; Baccala A A; Goemann M A; Clift S M; Ando D G; Levitsky H I; Cohen L K; Sanda M G; Mulligan R C; Partin A W; Carter H B; Piantadosi S; Marshall F F; Nelson W G
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Cancer research 1999;59(20):5160-8.
1999: Southwick P C; Catalona W J; Partin A W; Slawin K M; Brawer M K; Flanigan R C; Patel A; Richie J P; Walsh P C; Scardino P T; Lange P H; Gasior G H; Parson R E; Loveland K G
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
The Journal of urology 1999;162(4):1346-51.
1999: Pound C R; Christens-Barry O W; Gurganus R T; Partin A W; Walsh P C
Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
The Journal of urology 1999;162(4):1337-40.
1999: Polascik T J; Wang Z P; Shue M; Di S; Gurganus R T; Hortopan S C; Ts'o P O; Partin A W
Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells.
The Journal of urology 1999;162(3 Pt 1):749-52.
1999: Catalona W J; Partin A W; Finlay J A; Chan D W; Rittenhouse H G; Wolfert R L; Woodrum D L
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.
Urology 1999;54(2):220-4.
1999: Polascik T J; Oesterling J E; Partin A W
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
The Journal of urology 1999;162(2):293-306.
1999: Breslow N E; Partin A W; Lee B R; Guthrie K A; Beckwith J B; Green D M
Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2123-6.
1999: Williams A M; Simon I; Landis P K; Moser C; Christens-Barry W; Carter H B; Metter E J; Partin A W
Prostatic growth rate determined from MRI data: age-related longitudinal changes.
Journal of andrology 1999;20(4):474-80.
1999: Potter S R; Reckwitz T; Partin A W
The use of percent free PSA for early detection of prostate cancer.
Journal of andrology 1999;20(4):449-53.
1999: Ruska K M; Partin A W; Epstein J I; Kahane H
Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings.
Urology 1999;53(6):1179-83.
1999: Subong E N; Shue M J; Epstein J I; Briggman J V; Chan P K; Partin A W
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.
The Prostate 1999;39(4):298-304.
1999: Chon J K; Borkowski A; Partin A W; Isaacs J T; Jacobs S C; Kyprianou N
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
The Journal of urology 1999;161(6):2002-8.
1999: Lee B R; Roberts W W; Smith D G; Ko H W; Epstein J I; Lecksell K; Partin A W
Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate.
The Prostate 1999;39(3):213-8.
1999: Pound C R; Partin A W; Eisenberger M A; Chan D W; Pearson J D; Walsh P C
Natural history of progression after PSA elevation following radical prostatectomy.
JAMA : the journal of the American Medical Association 1999;281(17):1591-7.
1999: Micali S; Silver R I; Kaufman H S; Douglas V D; Marley G M; Partin A W; Moore R G; Kavoussi L R; Docimo S G
Measurement of urinary N-acetyl-beta-D-glucosaminidase to assess renal ischemia during laparoscopic operations.
Surgical endoscopy 1999;13(5):503-6.
1999: Polascik T J; Manyak M J; Haseman M K; Gurganus R T; Rogers B; Maguire R T; Partin A W
Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Cancer 1999;85(7):1586-92.
1999: Marks L S; Partin A W; Dorey F J; Gormley G J; Epstein J I; Garris J B; Macairan M L; Shery E D; Santos P B; Stoner E; deKernion J B
Long-term effects of finasteride on prostate tissue composition.
Urology 1999;53(3):574-80.
1999: Polascik T J; Hamper U; Lee B R; Dai Y; Hilton J; Magee C A; Crone J K; Shue M J; Ferrell M; Trapanotto V; Adiletta M; Partin A W
Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology.
Urology 1999;53(3):465-72; discussion 470-2.
1999: Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin A W; Roehrborn C G; Marberger M
Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Urology 1999;53(2):251-9.
1999: Sokoll L J; Partin A W; Nelson J B; Chan D W
Critical analysis of false elevations in PSA results reported with the Abbott AxSYM assay.
The Prostate 1999;38(1):79-80.
1999: Eisenberger C F; Walsh P C; Eisenberger M A; Chow N H; Partin A W; Mostwin J L; Marshall F F; Epstein J I; Schoenberg M
Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer.
Urology 1999;53(1):175-9.
1999: Carter H B; Epstein J I; Partin A W
Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.
Urology 1999;53(1):126-30.
1999: Carducci M A; Piantadosi S; Pound C R; Epstein J I; Simons J W; Marshall F F; Partin A W
Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma.
Urology 1999;53(1):44-9.
1999: Potter S R; Partin A W
Prostate biopsy schemes and the detection of prostate cancer.
Reviews in urology 1999;1(4):207-8.
1999: Partin A W; Djavan B
BPH Plus Prostate Cancer Therapy and Markers Featured at EAU: Highlights from the 14th Annual Congress of the European Association of Urology April 7-10, 1999, Stockholm, Sweden.
Reviews in urology 1999;1(4):180-92.
1999: Potter S R; Partin A W
Urinary incontinence after radical retropubic prostatectomy.
Reviews in urology 1999;1(2):97-8.
1999: Partin A W
Prostate Cancer Markers and Treatments Ranging From Gene Therapy to Cryosurgery Examined at AUA: Highlights from the American Urological Association 93rd Annual Meeting May 30-June 4, 1998, San Diego, Calif.
Reviews in urology 1999;1(2):82-91.
1998: Polascik T J; Partin A W; Pound C R; Marshall F F
Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis.
Urology 1998;52(6):995-9.
1998: Marshall F F; Chan D; Partin A W; Gurganus R; Hortopan S C
Minilaparotomy radical retropubic prostatectomy: technique and results.
The Journal of urology 1998;160(6 Pt 2):2440-5.
1998: Partin A W; Stutzman R E
Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy.
The Urologic clinics of North America 1998;25(4):581-9, viii.
1998: Murphy G P; Partin A
Workshop on Prostate Markers. International Union Against Cancer.
Cancer 1998;83(10):2233-8.
1998: Carlson G D; Calvanese C B; Partin A W
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases.
Urology 1998;52(3):455-61.
1998: Bova G S; Partin A W; Isaacs S D; Carter B S; Beaty T L; Isaacs W B; Walsh P C
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy.
The Journal of urology 1998;160(3 Pt 1):660-3.
1998: Rittenhouse H G; Finlay J A; Mikolajczyk S D; Partin A W
Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
Critical reviews in clinical laboratory sciences 1998;35(4):275-368.
1998: Polascik T J; Pearson J D; Partin A W
Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen.
Seminars in urologic oncology 1998;16(3):160-71.
1998: Pannek J; Partin A W
The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
Seminars in urologic oncology 1998;16(3):100-5.
1998: Miller L R; Partin A W; Chan D W; Bruzek D J; Dobs A S; Epstein J I; Walsh P C
Influence of radical prostatectomy on serum hormone levels.
The Journal of urology 1998;160(2):449-53.
1998: Epstein J I; Pound C R; Partin A W; Walsh P C
Disease progression following radical prostatectomy in men with Gleason score 7 tumor.
The Journal of urology 1998;160(1):97-100; discussion 101.
1998: Lee B R; Silver R I; Partin A W; Epstein J I; Gearhart J P
A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood.
Urology 1998;51(5):820-3.
1998: Wills M L; Sauvageot J; Partin A W; Gurganus R; Epstein J I
Ability of sextant biopsies to predict radical prostatectomy stage.
Urology 1998;51(5):759-64.
1998: Catalona W J; Partin A W; Slawin K M; Brawer M K; Flanigan R C; Patel A; Richie J P; deKernion J B; Walsh P C; Scardino P T; Lange P H; Subong E N; Parson R E; Gasior G H; Loveland K G; Southwick P C
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
JAMA : the journal of the American Medical Association 1998;279(19):1542-7.
1998: Simon I; Pound C R; Partin A W; Clemens J Q; Christens-Barry W A
Automated image analysis system for detecting boundaries of live prostate cancer cells.
Cytometry 1998;31(4):287-94.
1998: Lakshmanan Y; Subong E N; Partin A W
Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage.
The Journal of urology 1998;159(4):1354-8.
1998: Pannek J; Rittenhouse H G; Chan D W; Epstein J I; Walsh P C; Partin A W
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
The Journal of urology 1998;159(4):1238-42.
1998: Pannek J; Marks L S; Pearson J D; Rittenhouse H G; Chan D W; Shery E D; Gormley G J; Subong E N; Kelley C A; Stoner E; Partin A W
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
The Journal of urology 1998;159(2):449-53.
1998: Cadeddu J A; Partin A W; DeWeese T L; Walsh P C
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
The Journal of urology 1998;159(1):173-7; discussion 177-8.
1998: Woodrum D L; Brawer M K; Partin A W; Catalona W J; Southwick P C
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
The Journal of urology 1998;159(1):5-12.
1998: Lee B R; Caddedu J A; Janetschek G; Schulam P; Docimo S G; Moore R G; Partin A W; Kavoussi L R
International surgical telementoring: our initial experience.
Studies in health technology and informatics 1998;50():41-7.
1997: Murphy G P; Maguire R T; Rogers B; Partin A W; Nelp W B; Troychak M J; Ragde H; Kenny G M; Barren R J; Bowes V A; Gregorakis A K; Holmes E H; Boynton A L
Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
The Prostate 1997;33(4):281-5.
1997: Page W F; Braun M M; Partin A W; Caporaso N; Walsh P
Heredity and prostate cancer: a study of World War II veteran twins.
The Prostate 1997;33(4):240-5.
1997: Partin A W; Briggman J V; Subong E N; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey D S; Epstein J I
Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Urology 1997;50(5):800-8.
1997: Pannek J; Rittenhouse H G; Evans C L; Finlay J A; Bruzek D J; Cox J L; Chan D W; Subong E N; Partin A W
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Urology 1997;50(5):715-21.
1997: Walsh P C; Partin A W
Family history facilitates the early diagnosis of prostate carcinoma.
Cancer 1997;80(9):1871-4.
1997: Pannek J; Partin A W
Prostate-specific antigen: what's new in 1997.
Oncology (Williston Park, N.Y.) 1997;11(9):1273-8; discussion 1279-82.
1997: Cadeddu J A; Partin A W; Epstein J I; Walsh P C
Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.
Urology 1997;50(2):251-5.
1997: Ts'o P O; Pannek J; Wang Z P; Lesko S A; Bova G S; Partin A W
Detection of intact prostate cancer cells in the blood of men with prostate cancer.
Urology 1997;49(6):881-5.
1997: Marks L S; Partin A W; Gormley G J; Dorey F J; Shery E D; Garris J B; Subong E N; Stoner E; deKernion J B
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
The Journal of urology 1997;157(6):2171-8.
1997: Partin A W; Kattan M W; Subong E N; Walsh P C; Wojno K J; Oesterling J E; Scardino P T; Pearson J D
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
JAMA : the journal of the American Medical Association 1997;277(18):1445-51.
1997: Pound C R; Partin A W; Epstein J I; Walsh P C
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
The Urologic clinics of North America 1997;24(2):395-406.
1997: Carter H B; Partin A W; Luderer A A; Metter E J; Landis P; Chan D W; Fozard J L; Pearson J D
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.
Urology 1997;49(3):379-84.
1997: Wills M L; Hamper U M; Partin A W; Epstein J I
Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens.
Urology 1997;49(3):367-73.
1997: Sanda M G; Doehring C B; Binkowitz B; Beaty T H; Partin A W; Hale E; Stoner E; Walsh P C
Clinical and biological characteristics of familial benign prostatic hyperplasia.
The Journal of urology 1997;157(3):876-9.
1997: Silver R I; Partin A W; Epstein J I; Chan D W; Carter H B; Jeffs R D; Gearhart J P
Prostate-specific antigen in men born with bladder exstrophy.
Urology 1997;49(2):253-6.
1997: Silberman M A; Partin A W; Veltri R W; Epstein J I
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.
Cancer 1997;79(4):772-9.
1997: Pound C R; Walsh P C; Epstein J I; Chan D W; Partin A W
Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer.
World journal of urology 1997;15(6):373-7.
1996: Partin A W; Catalona W J; Southwick P C; Subong E N; Gasior G H; Chan D W
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.
Urology 1996;48(6A Suppl):55-61.
1996: Pannek J; Subong E N; Jones K A; Marschke P L; Epstein J I; Chan D W; Carter H B; Luderer A A; Partin A W
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
Urology 1996;48(6A Suppl):51-4.
1996: Thiel R P; Oesterling J E; Wojno K J; Partin A W; Chan D W; Carter H B; Stamey T A; Prestigiacomo A R; Brawer M K; Petteway J C; Carlson G; Luderer A A
Multicenter comparison of the diagnostic performance of free prostate-specific antigen.
Urology 1996;48(6A Suppl):45-50.
1996: Pearson J D; Luderer A A; Metter E J; Partin A W; Chan D W; Fozard J L; Carter H B
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Urology 1996;48(6A Suppl):4-9.
1996: Partin A W; Oesterling J E
The clinical usefulness of percent free-PSA.
Urology 1996;48(6A Suppl):1-3.
1996: Lee B R; Perlman E J; Partin A W; Jeffs R D; Gearhart J P
Evaluation of smooth muscle and collagen subtypes in normal newborns and those with bladder exstrophy.
The Journal of urology 1996;156(6):2034-6.
1996: Partin A W; Carter H B
The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
The Urologic clinics of North America 1996;23(4):531-40.
1996: Veltri R W; Miller M C; Partin A W; Coffey D S; Epstein J I
Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.
Urology 1996;48(5):685-91.
1996: Doehring C B; Sanda M G; Partin A W; Sauvageot J; Juo H; Beaty T H; Epstein J I; Hill G; Walsh P C
Histopathologic characterization of hereditary benign prostatic hyperplasia.
Urology 1996;48(4):650-3.
1996: Marks L S; Dorey F J; Rhodes T; Shery E D; Rittenhouse H; Partin A W; deKernion J B
Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
The Journal of urology 1996;156(3):1035-9.
1996: Smith R C; Partin A W; Epstein J I; Brendler C B
Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation.
The Journal of urology 1996;156(2 Pt 1):454-7; discussion 457-8.
1996: Weinstein M H; Partin A W; Veltri R W; Epstein J I
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.
Human pathology 1996;27(7):683-7.
1996: Niesel T; Partin A W; Walsh P C
Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain.
Urology 1996;48(1):91-4.
1996: Partin A W; Criley S R; Subong E N; Zincke H; Walsh P C; Oesterling J E
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
The Journal of urology 1996;155(4):1336-9.
1996: Epstein J I; Partin A W; Sauvageot J; Walsh P C
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up.
The American journal of surgical pathology 1996;20(3):286-92.
1996: Moore R G; Partin A W; Kavoussi L R
Role of laparoscopy in the diagnosis and treatment of prostate cancer.
Seminars in surgical oncology 1996;12(2):139-44.
1996: Moore R G; Adams J B; Partin A W; Docimo S G; Kavoussi L R
Telementoring of laparoscopic procedures: initial clinical experience.
Surgical endoscopy 1996;10(2):107-10.
1996: Partin A W
Prostate cancer--educating ourselves and our nonurological colleagues.
The Journal of urology 1996;155(2):610-1.
1996: Ben-Chaim J; Partin A W; Jeffs R D
Ureteral bladder augmentation using the lower pole ureter of a duplicated system.
Urology 1996;47(1):135-7.
1996: Partin A W; Piantadosi S; Subong E N; Kelly C A; Hortopan S; Chan D W; Wolfert R L; Rittenhouse H G; Carter H B
Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.
The Prostate. Supplement 1996;7():35-9.
1995: Partin A W; Adams J B; Moore R G; Kavoussi L R
Complete robot-assisted laparoscopic urologic surgery: a preliminary report.
Journal of the American College of Surgeons 1995;181(6):552-7.
1995: Kavoussi L R; Moore R G; Adams J B; Partin A W
Comparison of robotic versus human laparoscopic camera control .
The Journal of urology 1995;154(6):2134-6.
1995: Polascik T J; Pound C R; Meng M V; Partin A W; Marshall F F
Partial nephrectomy: technique, complications and pathological findings.
The Journal of urology 1995;154(4):1312-8.
1995: Quinlan D M; Partin A W; Walsh P C
Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?
Urology 1995;46(3 Suppl A):77-82.
1995: Adams J B; Schulam P G; Moore R G; Partin A W; Kavoussi L R
New laparoscopic suturing device: initial clinical experience.
Urology 1995;46(2):242-5.
1995: Moore R G; Partin A W; Adams J B; Kavoussi L R
Adhesion formation after transperitoneal nephrectomy: laparoscopic v open approach.
Journal of endourology / Endourological Society 1995;9(3):277-80.
1995: Partin A W; Piantadosi S; Sanda M G; Epstein J I; Marshall F F; Mohler J L; Brendler C B; Walsh P C; Simons J W
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.
Urology 1995;45(5):831-8.
1995: Cadeddu J A; Pearson J D; Lee B R; Landis P; Partin A W; Epstein J I; Carter H B
Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
Urology 1995;45(5):795-800.
1995: Carmichael M J; Veltri R W; Partin A W; Miller M C; Walsh P C; Epstein J I
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.
The Journal of urology 1995;153(3 Pt 2):1015-9.
1995: Partin A W; Criley S R; Steiner M S; Hsieh K; Simons J W; Lumadue J; Carter H B; Marshall F F
Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
Urology 1995;45(2):211-7.
1995: Gearhart J P; Lee B R; Partin A W; Epstein J I; Gosling J A
A quantitative histological evaluation of the dilated ureter of childhood. II: Ectopia, posterior urethral valves and the prune belly syndrome.
The Journal of urology 1995;153(1):172-6.
1995: Epstein J I; Carmichael M; Partin A W
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.
Urology 1995;45(1):81-6.
1995: Gearhart J P; Willmann J R; Beckwith J B; Epstein J; Partin A W
Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor.
Urology 1995;45(1):119-23.
1995: Marshall F F; Steinberg G D; Pound C R; Partin A W
Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection.
World journal of urology 1995;13(3):159-62.
1994: Mohler J L; Figlesthaler W M; Zhang X Z; Partin A W; Maygarden S J
Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma.
Cancer 1994;74(11):2996-3001.
1994: Rinker-Schaeffer C W; Partin A W; Isaacs W B; Coffey D S; Isaacs J T
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells.
The Prostate 1994;25(5):249-65.
1994: Partin A W; Page W F; Lee B R; Sanda M G; Miller R N; Walsh P C
Concordance rates for benign prostatic disease among twins suggest hereditary influence.
Urology 1994;44(5):646-50.
1994: Walsh P C; Partin A W; Epstein J I
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.
The Journal of urology 1994;152(5 Pt 2):1831-6.
1994: Partin A W; Oesterling J E
The clinical usefulness of prostate specific antigen: update 1994.
The Journal of urology 1994;152(5 Pt 1):1358-68.
1994: Kavoussi L R; Moore R G; Partin A W; Bender J S; Zenilman M E; Satava R M
Telerobotic assisted laparoscopic surgery: initial laboratory and clinical experience.
Urology 1994;44(1):15-9.
1994: Partin A W; Walsh P C
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
The Journal of urology 1994;152(1):172-3.
1994: Epstein J I; Carmichael M J; Partin A W; Walsh P C
Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications.
The Journal of urology 1994;151(6):1587-92.
1994: Partin A W; Lee B R; Carmichael M; Walsh P C; Epstein J I
Radical prostatectomy for high grade disease: a reevaluation 1994.
The Journal of urology 1994;151(6):1583-6.
1994: Partin A W; Pearson J D; Landis P K; Carter H B; Pound C R; Clemens J Q; Epstein J I; Walsh P C
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Urology 1994;43(5):649-59.
1994: Partin A W; Yoo J K; Crooks D; Epstein J I; Beckwith J B; Gearhart J P
Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques.
Journal of pediatric surgery 1994;29(3):456-60.
1994: Walsh P C; Partin A W
Treatment of early stage prostate cancer: radical prostatectomy.
Important advances in oncology 1994;():211-23.
1994: Veltri R W; Partin A W; Epstein J E; Marley G M; Miller C M; Singer D S; Patton K P; Criley S R; Coffey D S
Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Journal of cellular biochemistry. Supplement 1994;19():249-58.
1994: Partin A W; Coffey D S
Benign and malignant prostatic neoplasms: human studies.
Recent progress in hormone research 1994;49():293-331.
1993: Partin A W; Pound C R; Clemens J Q; Epstein J I; Walsh P C
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
The Urologic clinics of North America 1993;20(4):713-25.
1993: Cadeddu J A; Pearson J D; Partin A W; Epstein J I; Carter H B
Relationship between changes in prostate-specific antigen and prognosis of prostate cancer.
Urology 1993;42(4):383-9.
1993: Pound C R; Partin A W; Epstein J I; Simons J W; Marshall F F
Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma.
Urology 1993;42(3):243-8.
1993: Partin A W; Borland R N; Epstein J I; Brendler C B
Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration.
The Journal of urology 1993;150(1):142-6; discussion 146-8.
1993: Partin A W; Yoo J; Carter H B; Pearson J D; Chan D W; Epstein J I; Walsh P C
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
The Journal of urology 1993;150(1):110-4.
1993: Epstein J I; Carmichael M; Partin A W; Walsh P C
Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
The Journal of urology 1993;149(6):1478-81.
1993: Epner D E; Partin A W; Schalken J A; Isaacs J T; Coffey D S
Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma.
Cancer research 1993;53(9):1995-7.
1993: Borland R N; Partin A W; Epstein J I; Brendler C B
The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma.
The Journal of urology 1993;149(2):272-5.
1993: Partin A W; Getzenberg R H; CarMichael M J; Vindivich D; Yoo J; Epstein J I; Coffey D S
Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Cancer research 1993;53(4):744-6.
1993: Partin A W; Gearhart J P; Leonard M P; Leventhal B G; Yoo J K; Crooks D; Epstein J I; Beckwith J B
The use of nuclear morphometry to predict prognosis in pediatric urologic malignancies: a review.
Medical and pediatric oncology 1993;21(3):222-9.
1993: Tempany C M; Partin A W; Zerhouni E A; Zinreich S J; Walsh P C
The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
The Prostate 1993;22(1):39-42.
1992: Tardif C P; Partin A W; Qaqish B; Epstein J P; Mohler J L
Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1992;14(6):474-82.
1992: Lee B R; Partin A W; Epstein J I; Quinlan D M; Gosling J A; Gearhart J P
A quantitative histological analysis of the dilated ureter of childhood.
The Journal of urology 1992;148(5):1482-6.
1992: Epstein J I; Pizov G; Steinberg G D; Carter H B; Pitcock R; Armas O A; Partin A; Walsh P C
Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy.
The Journal of urology 1992;148(1):87-91.
1992: Partin A W; Steinberg G D; Pitcock R V; Wu L; Piantadosi S; Coffey D S; Epstein J I
Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.
Cancer 1992;70(1):161-8.
1992: Gearhart J P; Partin A W; Leventhal B; Beckwith J B; Epstein J I
The use of nuclear morphometry to predict response to therapy in Wilms' tumor.
Cancer 1992;69(3):804-8.
1992: Mohler J L; Partin A W; Epstein J I; Becker R L; Mikel U V; Sesterhenn I A; Mostofi F K; Gleason D F; Sharief Y; Coffey D S
Prediction of prognosis in untreated stage A2 prostatic carcinoma.
Cancer 1992;69(2):511-9.
1992: Partin A W; Carter H B; Epstein J I; Coffey D S
The biology of prostate cancer: new and future directions in predicting tumor behavior.
Monographs in pathology 1992;(34):198-218.
1992: Partin A W; Mohler J L; Coffey D S
Cell motility as an index of metastatic ability in prostate cancers: results with an animal model and with human cancer cells.
Cancer treatment and research 1992;59():121-30.
1991: Armas O A; Pizov G; Pitcock R V; Partin A W; Epstein J I
Nuclear morphology of prostatic carcinoma: comparison of computerized image analysis (CAS 200) versus video planimetry (DynaCELL).
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1991;4(6):763-7.
1991: Partin A W; Oesterling J E; Epstein J I; Horton R; Walsh P C
Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.
The Journal of urology 1991;145(2):405-9.
1990: Leonard M P; Partin A W; Epstein J I; Jeffs R D; Gearhart J P
Nuclear morphometry as a prognostic indicator for genitourinary rhabdomyosarcoma: a preliminary investigation.
The Journal of urology 1990;144(5):1222-6.
1990: Carter H B; Partin A W; Epstein J I; Chan D W; Walsh P C
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
The Journal of urology 1990;144(5):1167-70; discussion 1170-1.
1990: Partin A W; Walsh A C; Epstein J I; Leventhal B G; Gearhart J P
Nuclear morphometry as a predictor of response to therapy in Wilms tumor: a preliminary report.
The Journal of urology 1990;144(4):952-4.
1990: Murphy G F; Partin A W; Maygarden S J; Mohler J L
Nuclear shape analysis for assessment of prognosis in renal cell carcinoma.
The Journal of urology 1990;143(6):1103-7.
1990: Partin A W; Carter H B; Chan D W; Epstein J I; Oesterling J E; Rock R C; Weber J P; Walsh P C
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
The Journal of urology 1990;143(4):747-52.
1990: Christensen W N; Partin A W; Walsh P C; Epstein J I
Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage.
Cancer 1990;65(4):1021-7.
1990: Isaacs W B; Isaacs J T; Kyprianou N; Burgers J K; Alexander R B; Partin A W; Mohler J L; Marshall F F; Coffey D S
New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
European urology 1990;18 Suppl 2():33-5.
1989: Carter H B; Partin A W; Coffey D S
Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge.
The Journal of urology 1989;142(5):1338-41.
1989: Partin A W; Walsh A C; Pitcock R V; Mohler J L; Epstein J I; Coffey D S
A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis.
The Journal of urology 1989;142(5):1254-8.
1989: Ward W S; Partin A W; Coffey D S
DNA loop domains in mammalian spermatozoa.
Chromosoma 1989;98(3):153-9.
1989: Pienta K J; Partin A W; Coffey D S
Cancer as a disease of DNA organization and dynamic cell structure.
Cancer research 1989;49(10):2525-32.
1989: Weber J P; Oesterling J E; Peters C A; Partin A W; Chan D W; Walsh P C
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
The Journal of urology 1989;141(4):987-92.
1989: Quinlan D M; Nelson R J; Partin A W; Mostwin J L; Walsh P C
The rat as a model for the study of penile erection.
The Journal of urology 1989;141(3):656-61.
1989: Partin A W; Schoeniger J S; Mohler J L; Coffey D S
Fourier analysis of cell motility: correlation of motility with metastatic potential.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(4):1254-8.
1989: Partin A W; Epstein J I; Cho K R; Gittelsohn A M; Walsh P C
Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer.
The Journal of urology 1989;141(2):341-5.
1988: Partin A W; Isaacs J T; Treiger B; Coffey D S
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.
Cancer research 1988;48(21):6050-3.
1988: Mohler J L; Partin A W; Isaacs J T; Coffey D S
Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.
Cancer research 1988;48(15):4312-7.
1988: Mohler J L; Partin A W; Lohr W D; Coffey D S
Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system.
The Journal of urology 1988;139(5):1080-4.
1988: Mohler J L; Partin A W; Epstein J I; Lohr W D; Coffey D S
Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections.
The Journal of urology 1988;139(5):1085-90.
1987: Mohler J L; Partin A W; Coffey D S
Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model.
The Journal of urology 1987;138(1):168-70.
1987: Mohler J L; Partin A W; Coffey D S
Correlation of prognosis to nuclear roundness and to flow cytometric light scatter.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1987;9(2):156-64.
1987: Mohler J L; Partin A W; Isaacs W B; Coffey D S
Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells.
The Journal of urology 1987;137(3):544-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Alan Partin

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Alan Partin (preview)

All Publications